文献类型：期刊文章

作　　者：王玉平[1] 朱晓伟[1] 辛健[1] 郭妍妍[1] 徐向楠[1] 马宇衡[1]

机构地区：[1]内蒙古医科大学药学院药物化学教研室,内蒙古呼和浩特010110

出　　处：《Journal of Chinese Pharmaceutical Sciences》

基　　金：National Natural Science Foundation of China(Grant No.21362021);Inner Mongolia Natural Science Foundation(Grant No.2015MS0206)

年　　份：2017

卷　　号：26

期　　号：7

起止页码：467-478

语　　种：中文

收录情况：CAB、CAS、CSCD、CSCD2017_2018、DOAJ、EMBASE、IC、JST、SCOPUS、ZGKJHX、普通刊

摘　　要：As Bortezomib and Carfilzomib are approved to treat refractory multiple myeloma, 20 S proteasome has become a highly interested tumor therapeutic target. Because of drug resistance of Bortezomib and Carfilzomib, β-lactone natural products are used to treat cancer, arthritis, asthma, and Alzheimer’s diseases. Now the second generation drug candidates are developed, eg. Salinosporamide A（1）. This review is aiming to encapsulate the synthetic methods of β-lactone proteasome inhibitors, lactacystin（3） and its analogs.

关 键 词：LACTACYSTIN β-Lactone  PROTEASOME INHIBITORS

分 类 号：R914]